27642 Federal Register / Vol. 87, No. 89 / Monday, May 9, 2022 / Notices 

section 13(a) of the IBA authorizes the 

Board to ‘‘issue such rules, regulations, 

and orders as’’ it may deem necessary in 

order to perform its ‘‘respective duties 

and functions under this chapter and to 

administer and carry out the provisions 

and purposes of this chapter and 

prevent evasions thereof.’’ 

The FR Y–7 is authorized by sections 

8(a) and 13(a) of the IBA and section 

5(c)(1) of the BHC Act. 

The FR Y–10 and FR Y–10E are 

authorized by the Board’s reporting 

authorities, which are located in section 

5(c)(1) of the BHC Act for BHCs, section 

10(b)(2) of HOLA for SLHCs, and 

section 618 of the Dodd-Frank Act for 

securities holding companies. The 

Board is authorized to require state 

member banks and agreement and Edge 

corporations to file the FR Y–10 by 

reporting authorities located in sections 

9(6), 25, and 25A of the Federal Reserve 

Act (FRA) (for state member banks, 

agreement corporations, and Edge 

corporations, respectively) (12 U.S.C. 

324, 602, and 625, respectively). 

Similarly, information collection from 

national banks under the FR Y–10 and 

FR Y–10E with respect to their foreign 

branches, their investments made under 

Subpart A of Regulation K, and foreign 

branches of their foreign subsidiaries 

that are investments made under 

Subpart A of Regulation K, is authorized 

by the reporting authorities located in 

sections 25 and 25A of the FRA. The 

Board has the authority to require FBOs 

to file the FR Y–10 under sections 8(a) 

and 13(a) of the IBA and section 5(c)(1) 

of the BHC Act. 

Information collections under the FR 

Y–6, FR Y–7, and FR Y–10 are 

mandatory. Information collections 

under the FR Y–10E are voluntary. 

Individual respondents may request 

that information submitted to the Board 

through the FR Y–6, FR Y–7, FR Y–10, 

and FR Y–10E be kept confidential. If a 

respondent requests confidential 

treatment, the Board will determine 

whether the information is entitled to 

confidential treatment on a case-by-case 

basis. To the extent a respondent 

submits nonpublic commercial or 

financial information, which is both 

customarily and actually treated as 

private by the respondent, the 

respondent may request confidential 

treatment pursuant to exemption 4 of 

the Freedom of Information Act (FOIA) 

(5 U.S.C. 552(b)(4)). To the extent a 

respondent submits personal, medical, 

or similar files, the disclosure of which 

would constitute an unwarranted 

invasion of privacy, the respondent may 

request confidential treatment pursuant 

to exemption 6 of the FOIA (5 U.S.C. 

552(b)(6)). Additionally, personal home 

addresses of securities holders 

submitted in response to the FR Y–7 

will be treated as confidential pursuant 

to exemption 6 of the FOIA. 

Board of Governors of the Federal Reserve 

System. 

Dated: May 3, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–09850 Filed 5–6–22; 8:45 am] 

BILLING CODE 6210–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (Act) (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

applications are set forth in paragraph 7 

of the Act (12 U.S.C. 1817(j)(7)). 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in paragraph 7 of 

the Act. 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than May 24, 2022. 

A. Federal Reserve Bank of 

Minneapolis (Chris P. Wangen, 

Assistant Vice President), 90 Hennepin 

Avenue, Minneapolis, Minnesota 

55480–0291. Comments can also be sent 

electronically to MA@mpls.frb.org. 

1. The Williams Family 2021 

Irrevocable Trust Agreement and James 

L. Williams III, individually, and as 

trustee, both of Casselton, North Dakota; 

to join the Williams Family Group, a 

group acting in concert, to retain voting 

shares of First Financial Corporation, 

and thereby indirectly retain voting 

shares of BankNorth, both of Arthur, 

North Dakota. 

Board of Governors of the Federal Reserve 

System, May 4, 2022. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–09930 Filed 5–6–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Patient Safety Organizations: 

Voluntary Relinquishment for the Ohio 

Patient Safety Institute 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), Department of 

Health and Human Services (HHS). 

ACTION: Notice of delisting. 

SUMMARY: The Patient Safety and 

Quality Improvement Final Rule 

(Patient Safety Rule) authorizes AHRQ, 

on behalf of the Secretary of HHS, to list 

as a patient safety organization (PSO) an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ by 

the Secretary if it is found to no longer 

meet the requirements of the Patient 

Safety and Quality Improvement Act of 

2005 (Patient Safety Act) and Patient 

Safety Rule, when a PSO chooses to 

voluntarily relinquish its status as a 

PSO for any reason, or when a PSO’s 

listing expires. AHRQ accepted a 

notification of proposed voluntary 

relinquishment from the Ohio Patient 

Safety Institute, PSO number P0041, of 

its status as a PSO, and has delisted the 

PSO accordingly. 

DATES: The delisting was effective at 

12:00 Midnight ET (2400) on April 30, 

2022. 

ADDRESSES: The directories for both 

listed and delisted PSOs are ongoing 

and reviewed weekly by AHRQ. Both 

directories can be accessed 

electronically at the following HHS 

website: http://www.pso.ahrq.gov/listed. 

FOR FURTHER INFORMATION CONTACT: 

Cathryn Bach, Center for Quality 

Improvement and Patient Safety, AHRQ, 

5600 Fishers Lane, MS 06N100B, 

Rockville, MD 20857; Telephone (toll 

free): (866) 403–3697; Telephone (local): 

(301) 427–1111; TTY (toll free): (866) 

438–7231; TTY (local): (301) 427–1130; 

Email: pso@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background 

The Patient Safety Act, 42 U.S.C. 

299b-21 to 299b-26, and the related 

Patient Safety Rule, 42 CFR part 3, 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 89 / Monday, May 9, 2022 / Notices 27643 

published in the Federal Register on 

November 21, 2008 (73 FR 70732– 

70814), establish a framework by which 

individuals and entities that meet the 

definition of provider in the Patient 

Safety Rule may voluntarily report 

information to PSOs listed by AHRQ, on 

a privileged and confidential basis, for 

the aggregation and analysis of patient 

safety work product. 

The Patient Safety Act authorizes the 

listing of PSOs, which are entities or 

component organizations whose 

mission and primary activity are to 

conduct activities to improve patient 

safety and the quality of health care 

delivery. 

HHS issued the Patient Safety Rule to 

implement the Patient Safety Act. 

AHRQ administers the provisions of the 

Patient Safety Act and Patient Safety 

Rule relating to the listing and operation 

of PSOs. The Patient Safety Rule 

authorizes AHRQ to list as a PSO an 

entity that attests that it meets the 

statutory and regulatory requirements 

for listing. A PSO can be ‘‘delisted’’ if 

it is found to no longer meet the 

requirements of the Patient Safety Act 

and Patient Safety Rule, when a PSO 

chooses to voluntarily relinquish its 

status as a PSO for any reason, or when 

a PSO’s listing expires. Section 3.108(d) 

of the Patient Safety Rule requires 

AHRQ to provide public notice when it 

removes an organization from the list of 

PSOs. 

AHRQ has accepted a notification of 

proposed voluntary relinquishment 

from the Ohio Patient Safety Institute to 

voluntarily relinquish its status as a 

PSO. Accordingly, the Ohio Patient 

Safety Institute, PSO number P0041, 

was delisted effective at 12:00 Midnight 

ET (2400) on April 30, 2022. 

Ohio Patient Safety Institute has 

patient safety work product (PSWP) in 

its possession. The PSO will meet the 

requirements of section 3.108(c)(2)(i) of 

the Patient Safety Rule regarding 

notification to providers that have 

reported to the PSO and of section 

3.108(c)(2)(ii) regarding disposition of 

PSWP consistent with section 

3.108(b)(3). According to section 

3.108(b)(3) of the Patient Safety Rule, 

the PSO has 90 days from the effective 

date of delisting and revocation to 

complete the disposition of PSWP that 

is currently in the PSO’s possession. 

More information on PSOs can be 

obtained through AHRQ’s PSO website 

at http://www.pso.ahrq.gov. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–09843 Filed 5–6–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Solicitation for Nominations for 

Membership To Serve on Initial Review 

Group for Scientific Peer Review 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Request for nominations for 

membership to serve on initial review 

group for scientific peer review. 

SUMMARY: This is to invite the public to 

nominate members to the Agency for 

Healthcare Research and Quality 

(AHRQ) Initial Review Group (IRG) 

responsible for the scientific peer 

review of AHRQ grant applications. The 

AHRQ IRG conducts scientific and 

technical review for health services 

research grant applications and is 

comprised of five subcommittees or 

study sections, each with a particular 

research focus. AHRQ is seeking 

nominations for scientific reviewers in 

specific competency domains to 

evaluate grant applications. 

DATES: Nominations should be received 

on or before June 1, 2022. 

ADDRESSES: Nominations should be 

submitted by email to dsr@ahrq.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Celeste Torio, Ph.D., MPH., AHRQ, 

(301) 427–1664 or by email at 

celeste.torio@ahrq.hhs.gov. 

SUPPLEMENTARY INFORMATION: This is to 

invite the public to nominate members 

to the Agency for Healthcare Research 

and Quality (AHRQ) Initial Review 

Group (IRG) responsible for the 

scientific peer review of AHRQ grant 

applications. AHRQ is required to 

conduct appropriate scientific peer 

review of grant applications pursuant to 

42 U.S.C. 299c–1. The AHRQ IRG 

conducts scientific and technical review 

for health services research grant 

applications and is comprised of five 

subcommittees or study sections, each 

with a particular research focus. AHRQ 

is seeking nominations for scientific 

reviewers in specific competency 

domains to evaluate grant applications. 

AHRQ’s mission is to produce 

evidence to make health care safer, 

higher quality, more accessible, 

equitable, and affordable, and to work 

within the U.S. Department of Health 

and Human Services (DHHS) and with 

other partners to make sure that the 

evidence is understood and used. AHRQ 

works to fulfill its mission by 

supporting health services research, 

evaluation, demonstration, 

dissemination, and training grants. 

The peer review of AHRQ grant 

applications involves an assessment 

conducted by panels of qualified experts 

established according to scientific 

disciplines or medical specialty areas. 

Members of the IRG will be selected 

based upon their training and 

experience in relevant scientific and 

technical fields, taking in account, 

among other factors: (1) The level of 

formal education and pertinent 

expertise and experience; (2) extent of 

engagement in relevant research; (3) 

extent of professional recognition; (4) 

need for specialization in relevant field; 

and (5) appropriate representation based 

on gender, racial/ethnic origin, and 

geography. See 42 CFR 67.15(a)(2). 

The IRG is comprised of five 

subcommittees, or study sections, each 

with a particular emphasis around 

which peer reviewer expertise is 

assembled. AHRQ seeks nominations for 

each of the subcommittee competency 

domains described below: 

Health Care Effectiveness and 

Outcomes Research: End-stage renal 

disease; cardiovascular disease; 

pediatrics; pharmacologist in opioid 

management; biostatisticians in health 

services research; health disparities and 

social determinants of health. 

Healthcare Safety and Quality 

Improvement Research: Pharmacists 

with expertise in informatics; infectious 

diseases specialists; geriatricians; 

surgeons with a specialty in diagnostic 

error; health disparities and social 

determinants of health. 

Healthcare Information Technology 

Research: Biomedical and consumer 

health informatics; family medicine; 

health care data analysis; health 

information technology; health services 

research in patient-oriented research; 

electronic health record and data for 

research; population-based studies in 

medicine; epidemiology; telehealth/ 

telemedicine; emergency medicine; 

insurance benefit design; chronic 

condition care; natural language 

processing and machine learning; social 

networking and its determinants of 

health; health disparities and social 

determinants of health. 

Healthcare Systems and Value 

Research: Health statistics; health care 

outcome research; evaluation and 

survey methods; health system and 

service research; health care policy 

research; health economics research; 

large database analysis; private health 

insurance/Medicaid and Medicare; 

learning laboratory development; health 

disparities and social determinants of 

health. 

Health Care Research Training: 

Clinicians with knowledge of health 

policy; Medicare and Medicaid; 


khammond on DSKJM1Z7X2PROD with NOTICES